<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="protein or the enzyme neuraminidase. Combination therapy with Interferon-α and" exact="ribavirin" post="remains the backbone treatment for chronic hepatitis C; the"/>
 <result pre="Some antiviral drugs possess multiple potential clinical applications, such as" exact="ribavirin" post="for the treatment of chronic hepatitis C and respiratory"/>
 <result pre="treatment of chronic hepatitis C and respiratory syncytial virus and" exact="cidofovir" post="for the treatment of cytomegalovirus and other DNA viruses."/>
 <result pre="discussed in these sections possess other potential applications, such as" exact="ribavirin" post="for the treatment of respiratory syncytial virus (RSV) and"/>
 <result pre="ribavirin for the treatment of respiratory syncytial virus (RSV) and" exact="cidofovir" post="for the treatment of cytomegalovirus (CMV) and other DNA"/>
 <result pre="CMV disease, gastrointestinal disease, pneumonia, and encephalitis Transition to oral" exact="valganciclovir" post="on clinical and virologic improvement Duration of therapy is"/>
 <result pre="CMV disease High risk of nephrotoxicity; requires concomitant hydration and" exact="probenecid" post="use Duration of therapy is guided by CMV surveillance"/>
 <result pre="no longer a preferred drug because of its poor bioavailability;" exact="valganciclovir" post="is preferred Valacyclovir (oral) 2 g orally 4 times"/>
 <result pre="(IV) 5 mg/kg IV every 12 h Less preferred than" exact="valganciclovir" post="because of the logistics of IV administration Oral ganciclovir"/>
 <result pre="than valganciclovir because of the logistics of IV administration Oral" exact="ganciclovir" post="should not be used for treating active CMV infection"/>
 <result pre="until immune reconstitution For sight-threatening retinitis, use in combination with" exact="ganciclovir" post="intraocular implant (see below) Ganciclovir (IV) Induction: 5 mg/kg"/>
 <result pre="until immune reconstitution For sight-threatening retinitis, use in combination with" exact="ganciclovir" post="intraocular implant (see below) Ganciclovir (intraocular implant) One sustained-release"/>
 <result pre="6–8 mo until immune reconstitution Use in combination with systemic" exact="ganciclovir" post="(or valganciclovir) because of the systemic nature of CMV"/>
 <result pre="CMV disease High risk of nephrotoxicity; requires concomitant hydration and" exact="probenecid" post="use CMV disease other than retinitis in HIV-infected patients"/>
 <result pre="CMV disease High risk of nephrotoxicity; requires concomitant hydration and" exact="probenecid" post="use aCMV = cytomegalovirus; HIV = human immunodeficiency virus;"/>
 <result pre="of acyclovir may still be beneficial in immunocompromised patients. Short-course" exact="prednisone" post="may be added as an adjunct to acyclovir treatment"/>
 <result pre="during the early period after transplant in patients not receiving" exact="ganciclovir" post="or valganciclovir prophylaxis.14 Acyclovir is generally well tolerated. However,"/>
 <result pre="early period after transplant in patients not receiving ganciclovir or" exact="valganciclovir" post="prophylaxis.14 Acyclovir is generally well tolerated. However, IV acyclovir"/>
 <result pre="available as an IV formulation, and an oral prodrug of" exact="cidofovir" post="(known as CMX-001) is under clinical development.28 This investigational"/>
 <result pre="is under clinical development.28 This investigational lipid ester formulation of" exact="cidofovir" post="has enhanced bioavailability, resulting in improved 50% inhibitory concentrations.28"/>
 <result pre="resulting in improved 50% inhibitory concentrations.28 Direct intraocular injection of" exact="cidofovir" post="is contraindicated due to ocular hypotony.27 Serum cidofovir concentrations"/>
 <result pre="injection of cidofovir is contraindicated due to ocular hypotony.27 Serum" exact="cidofovir" post="concentrations decline rapidly after IV infusion, with a half-life"/>
 <result pre="hours. Cidofovir is eliminated by glomerular filtration and tubular secretion;" exact="probenecid" post="reduces its excretion by blocking tubular secretion.29, 30 Cidofovir"/>
 <result pre="thereby halting viral DNA synthesis.27 The major clinical indication for" exact="cidofovir" post="is the treatment of CMV retinitis in HIV-infected patients"/>
 <result pre="CMV disease resistant or unresponsive to ganciclovir.32 Because activation of" exact="cidofovir" post="does not rely on viral kinases, it retains activity"/>
 <result pre="UL97 mutation and HSV with the TK mutation.33 Resistance to" exact="cidofovir" post="occurs when the virus develops mutations in the DNA"/>
 <result pre="Famciclovir Famciclovir is a diacetyl 6-deoxy analogue of penciclovir. Oral" exact="famciclovir" post="is rapidly absorbed and achieves a bioavailability of 77%.51"/>
 <result pre="of 77%.51 Famciclovir is metabolized into penciclovir, reaching peak plasma" exact="penciclovir" post="concentrations within 1 hour. Because of extensive hepatic metabolism,"/>
 <result pre="within 1 hour. Because of extensive hepatic metabolism, virtually no" exact="famciclovir" post="is detectable in plasma.51 Famciclovir is excreted renally as"/>
 <result pre="famciclovir is detectable in plasma.51 Famciclovir is excreted renally as" exact="penciclovir" post="and its 6-deoxy precursor.9 Famciclovir is active against HSV-1,"/>
 <result pre="extent, against EBV. Its mechanism of action is through penciclovir;" exact="penciclovir" post="triphosphate inhibits herpes DNA synthesis by acting as a"/>
 <result pre="substrate for viral DNA polymerase. The major clinical indications for" exact="famciclovir" post="use are treatment of herpes zoster, recurrent genital herpes,52"/>
 <result pre="varicella in HIV-infected patients. The most common adverse effects of" exact="famciclovir" post="are headache and nausea.54 Rare adverse events include jaundice,"/>
 <result pre="of standard CMV therapies, or whose virus is resistant to" exact="ganciclovir" post="and foscarnet.55, 56, 57 The main adverse effect of"/>
 <result pre="CMV diseases in immunocompromised patients, especially those unable to tolerate" exact="ganciclovir" post="and those infected with ganciclovir-resistant virus.60, 61 Foscarnet is"/>
 <result pre="CMV.65 It is available in oral and parenteral formulations. Oral" exact="ganciclovir" post="is poorly absorbed, with a bioavailability of only 5%.65"/>
 <result pre="5%.65 Management of active CMV disease is therefore with IV" exact="ganciclovir" post="or its oral valyl prodrug valganciclovir. Intravitreal ganciclovir implants"/>
 <result pre="with IV ganciclovir or its oral valyl prodrug valganciclovir. Intravitreal" exact="ganciclovir" post="implants are also available, with minimal systemic absorption. Ganciclovir"/>
 <result pre="herpes simplex keratitis, and CMV prophylaxis in transplant recipients. Intravenous" exact="ganciclovir" post="may also be used to treat other forms of"/>
 <result pre="disease, such as colitis or esophagitis. Induction therapy with IV" exact="ganciclovir" post="for CMV retinitis in patients with AIDS has an"/>
 <result pre="95% in stabilizing disease.68 Because it is poorly absorbed, oral" exact="ganciclovir" post="should not be used for induction treatment of CMV"/>
 <result pre="or progresses in patients with advanced AIDS, oral or IV" exact="ganciclovir" post="(or valganciclovir) is given as maintenance therapy until immune"/>
 <result pre="given as maintenance therapy until immune reconstitution is achieved.69 Intravitreal" exact="ganciclovir" post="may also be surgically implanted for the treatment of"/>
 <result pre="treatment should be used together with systemic therapy with IV" exact="ganciclovir" post="or oral valganciclovir therapy. Oral ganciclovir may be used"/>
 <result pre="used together with systemic therapy with IV ganciclovir or oral" exact="valganciclovir" post="therapy. Oral ganciclovir may be used to prevent CMV"/>
 <result pre="systemic therapy with IV ganciclovir or oral valganciclovir therapy. Oral" exact="ganciclovir" post="may be used to prevent CMV in patients with"/>
 <result pre="era of highly active antiretroviral therapy. Although IV and oral" exact="ganciclovir" post="have also been used to prevent CMV disease in"/>
 <result pre="also been used to prevent CMV disease in transplant recipients," exact="valganciclovir" post="is currently the preferred drug for this indication.60, 61,"/>
 <result pre="currently the preferred drug for this indication.60, 61, 70 Intravenous" exact="ganciclovir" post="is also used as a first-line treatment of CMV"/>
 <result pre="creatinine and liver enzymes. Neurotoxicity may occur occasionally. Resistance to" exact="ganciclovir" post="occurs most commonly in severely immunocompromised patients with prolonged"/>
 <result pre="prolonged exposure to the drug. The most common mechanism for" exact="ganciclovir" post="resistance is UL97 gene mutation71; this mutation leads to"/>
 <result pre="viral kinase that is necessary for the initial phosphorylation of" exact="ganciclovir" post="into its active form. A less common mechanism is"/>
 <result pre="available as topical therapy for mucocutaneous herpes. For systemic use," exact="penciclovir" post="has been reformulated into the oral prodrug famciclovir. The"/>
 <result pre="reformulated into the oral prodrug famciclovir. The antiviral activity of" exact="penciclovir" post="is similar to that of acyclovir, with efficacy against"/>
 <result pre="for prevention of CMV disease in kidney transplant recipients.78 Although" exact="ganciclovir" post="is the backbone for CMV prevention in transplant recipients,"/>
 <result pre="Valganciclovir Valganciclovir is the L-valyl ester prodrug of ganciclovir. Oral" exact="valganciclovir" post="is well absorbed and converted to ganciclovir by first-pass"/>
 <result pre="of ganciclovir. Oral valganciclovir is well absorbed and converted to" exact="ganciclovir" post="by first-pass intestinal or hepatic metabolism.79 The bioavailability of"/>
 <result pre="ganciclovir by first-pass intestinal or hepatic metabolism.79 The bioavailability of" exact="ganciclovir" post="after valganciclovir administration is about 60%, and peak plasma"/>
 <result pre="first-pass intestinal or hepatic metabolism.79 The bioavailability of ganciclovir after" exact="valganciclovir" post="administration is about 60%, and peak plasma concentrations are"/>
 <result pre="CMV retinitis in patients with AIDS.83 For immediate sight-threatening lesions," exact="valganciclovir" post="is used in combination with an intravitreal ganciclovir implant."/>
 <result pre="sight-threatening lesions, valganciclovir is used in combination with an intravitreal" exact="ganciclovir" post="implant. Valganciclovir is also used for preventing CMV disease"/>
 <result pre="kidney, heart, or kidney-pancreas transplants.61, 84 In the United States," exact="valganciclovir" post="is not approved for preventing CMV disease in liver"/>
 <result pre="higher incidence of tissue-invasive CMV disease in patients who received" exact="valganciclovir" post="vs oral ganciclovir prophylaxis. In other countries, valganciclovir is"/>
 <result pre="tissue-invasive CMV disease in patients who received valganciclovir vs oral" exact="ganciclovir" post="prophylaxis. In other countries, valganciclovir is used for preventing"/>
 <result pre="who received valganciclovir vs oral ganciclovir prophylaxis. In other countries," exact="valganciclovir" post="is used for preventing CMV disease in all solid"/>
 <result pre="Valganciclovir was recently demonstrated to be as effective as IV" exact="ganciclovir" post="for treating mild to moderate CMV disease in transplant"/>
 <result pre="as diarrhea, nausea, and vomiting, may be observed. Resistance to" exact="valganciclovir" post="occurs through mechanisms identical to those underlying ganciclovir resistance,"/>
 <result pre="Resistance to valganciclovir occurs through mechanisms identical to those underlying" exact="ganciclovir" post="resistance, ie, through mutations in the UL97 gene, which"/>
 <result pre="keratitis and acute keratoconjunctivitis.90 Once phosphorylated into its active form," exact="vidarabine" post="inhibits viral DNA polymerase. Adverse effects of ophthalmic vidarabine"/>
 <result pre="form, vidarabine inhibits viral DNA polymerase. Adverse effects of ophthalmic" exact="vidarabine" post="include irritation, pain, photophobia, lacrimation, and occlusion of the"/>
 <result pre="in elderly patients and those taking neuroaffective drugs. Emergence of" exact="amantadine" post="resistance has limited its use in the clinical setting.94,"/>
 <result pre="2 to 4 days of treatment. Because of widespread resistance," exact="amantadine" post="is no longer recommended for empiric treatment of influenza.94,"/>
 <result pre="is excreted in the urine. The mechanism of action of" exact="rimantadine" post="is similar to that of amantadine; it inhibits the"/>
 <result pre="limited by drug resistance.96, 97 A few trials that compared" exact="amantadine" post="and rimantadine suggested similar efficacy; however, neurologic adverse events"/>
 <result pre="drug resistance.96, 97 A few trials that compared amantadine and" exact="rimantadine" post="suggested similar efficacy; however, neurologic adverse events are less"/>
 <result pre="rimantadine. Neuraminidase Inhibitors Oseltamivir. Oseltamivir phosphate is a prodrug of" exact="oseltamivir" post="carboxylate, which is an inhibitor of neuraminidase that is"/>
 <result pre="in the replication of influenza A and B viruses.98 Oral" exact="oseltamivir" post="is well absorbed and reaches peak serum concentrations in"/>
 <result pre="and reaches peak serum concentrations in 1 hour. Bioavailability of" exact="oseltamivir" post="phosphate is at least 75%. The prodrug oseltamivir phosphate"/>
 <result pre="Bioavailability of oseltamivir phosphate is at least 75%. The prodrug" exact="oseltamivir" post="phosphate undergoes extensive hepatic metabolism via ester hydrolysis. More"/>
 <result pre="hepatic metabolism via ester hydrolysis. More than 99% of active" exact="oseltamivir" post="carboxylate is excreted renally. Oseltamivir carboxylate, the active drug"/>
 <result pre="influenza A and B, including pandemic strains. For this indication," exact="oseltamivir" post="should be started within 48 hours of exposure and"/>
 <result pre="outbreak. A systematic review reported no statistically significant difference between" exact="oseltamivir" post="and zanamivir prophylaxis for preventing symptomatic influenza among immunocompetent"/>
 <result pre="systematic review reported no statistically significant difference between oseltamivir and" exact="zanamivir" post="prophylaxis for preventing symptomatic influenza among immunocompetent adults.100 The"/>
 <result pre="influenza among immunocompetent adults.100 The most common adverse effects of" exact="oseltamivir" post="are nausea, vomiting, diarrhea, abdominal pain, insomnia, and vertigo."/>
 <result pre="the neuraminidase gene, such as R292K101 and H274Y,98 account for" exact="oseltamivir" post="resistance. Surveillance conducted during the 2009 H1N1 influenza pandemic"/>
 <result pre="is not available orally since it is poorly absorbed.106 Inhaled" exact="zanamivir" post="produces high concentrations in the respiratory tract where influenza"/>
 <result pre="influenza virus infection occurs. About 4% to 20% of inhaled" exact="zanamivir" post="is absorbed systemically, producing peak serum concentrations at 1"/>
 <result pre="is excreted in the feces.106 The mechanism of action of" exact="zanamivir" post="is similar to oseltamivir, by inhibiting neuraminidase, which is"/>
 <result pre="of newly formed viral particles from infected cells.106 For treatment," exact="zanamivir" post="is given by inhalation twice daily for 5 days,"/>
 <result pre="IV to treat critically ill patients with influenza.107, 108 Inhaled" exact="zanamivir" post="is well tolerated.106 Acute bronchospasm with decline in respiratory"/>
 <result pre="SC IFN-α.114 Likewise, SC peginterferon-α may be more effective than" exact="lamivudine" post="in hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients"/>
 <result pre="HBeAg-negative patients with CHB,115, 116, 117 and the addition of" exact="lamivudine" post="to peginterferon-α did not significantly enhance efficacy.118 Interferon-α is"/>
 <result pre="CHC.124, 125, 126 However, combination therapy with IFN-α and oral" exact="ribavirin" post="is more effective than either drug used alone.127 Combining"/>
 <result pre="is more effective than either drug used alone.127 Combining oral" exact="ribavirin" post="with peginterferon-α may be more effective than combining it"/>
 <result pre="of Liver Diseases130 recommends once-weekly SC peginterferon-α combined with oral" exact="ribavirin" post="as the first line of treatment of CHC. The"/>
 <result pre="rate of intolerance to a combination regimen of IFN-α and" exact="ribavirin" post="is higher and the rate of sustained virologic response"/>
 <result pre="plus ribavirin.132 A lower SVR rate to combination peginterferon-α plus" exact="ribavirin" post="therapy was observed in patients coinfected with HCV genotype"/>
 <result pre="In general, the guidelines recommend combination therapy with peginterferon-α and" exact="ribavirin" post="for 48 weeks. Interferons are generally not recommended in"/>
 <result pre="guanine, is available in oral, aerosolized, and IV formulations. Oral" exact="ribavirin" post="is absorbed extensively, but its bioavailability is only 65%"/>
 <result pre="bioavailability is only 65% because of first-pass metabolism. Peak plasma" exact="ribavirin" post="concentrations occur within 1 to 2 hours after oral"/>
 <result pre="times higher after 4 weeks of treatment. Administration of aerosolized" exact="ribavirin" post="leads to high concentrations in the respiratory tract, with"/>
 <result pre="leads to high concentrations in the respiratory tract, with some" exact="ribavirin" post="absorbed systemically. Ribavirin is mainly excreted in the urine.149"/>
 <result pre="mainly excreted in the urine.149 The mechanism of action of" exact="ribavirin" post="is known to be diverse but is not completely"/>
 <result pre="its antiviral activity is reversed by guanosine. Its triphosphorylated form," exact="ribavirin" post="triphosphate, is a potent competitive inhibitor of inosine monophosphate"/>
 <result pre="triphosphorylated form, ribavirin triphosphate, is a potent competitive inhibitor of" exact="inosine" post="monophosphate dehydrogenase, influenza virus RNA polymerase, and mRNA guanylyltransferase."/>
 <result pre="in vitro activity and its activity against human infections. Oral" exact="ribavirin" post="is approved for use, in combination with IFN-α or"/>
 <result pre="transplant recipients. When used for the treatment of RSV pneumonia," exact="ribavirin" post="is usually given by the aerosol route, which delivers"/>
 <result pre="which delivers high concentrations at the site of infection.152 Oral" exact="ribavirin" post="has also been used with good outcomes.153 Ribavirin has"/>
 <result pre="fever,160, 161 Bolivian hemorrhagic fever,162 and hantavirus pulmonary syndrome.163 Aerosolized" exact="ribavirin" post="can cause sudden deterioration of respiratory function and cardiovascular"/>
 <result pre="deterioration of respiratory function and cardiovascular effects. Precipitation of inhaled" exact="ribavirin" post="may occur in ventilatory tubings. Hemolytic anemia occurs commonly,154"/>
 <result pre="may occur in ventilatory tubings. Hemolytic anemia occurs commonly,154 and" exact="ribavirin" post="should not be given to patients with preexisting medical"/>
 <result pre="suicidal ideation, and relapse of drug abuse may occur, and" exact="ribavirin" post="is contraindicated in patients with a history of, or"/>
 <result pre="Adefovir 10 mg orally once daily Acyclic nucleotide analogue of" exact="adenosine" post="monophosphate Nephrotoxicity Lactic acidosis Rebound hepatitis rtN236T is most"/>
 <result pre="orally once daily Nucleoside analogue of cytidine Very similar to" exact="lamivudine" post="Used often in combination with tenofovir Lactic acidosis Rebound"/>
 <result pre="cytidine Very similar to lamivudine Used often in combination with" exact="tenofovir" post="Lactic acidosis Rebound hepatitis rtM204V/I provides cross-resistance with lamivudine"/>
 <result pre="with tenofovir Lactic acidosis Rebound hepatitis rtM204V/I provides cross-resistance with" exact="lamivudine" post="Entecavir 0.5 mg orally once daily for treatment-naive patients"/>
 <result pre="orally once daily Acyclic nucleoside phosphonate di ester analogue of" exact="adenosine" post="monophosphate One of the most potent anti-HBV drugs Nephrotoxicity"/>
 <result pre="competitive substrate for the HBV DNA polymerase. All drugs except" exact="telbivudine" post="have anti-HBV properties, and all patients with chronic hepatitis"/>
 <result pre="hepatomegaly. Adefovir. Adefovir dipivoxil is an acyclic nucleotide analogue of" exact="adenosine" post="monophosphate.164 Oral adefovir dipivoxil is rapidly absorbed and converted"/>
 <result pre="such as lamivudine.165 However, concomitant use with the related drug" exact="tenofovir" post="disoproxil fumarate is not recommended because of the augmented"/>
 <result pre="cytidine. Although not currently approved for the treatment of CHB," exact="emtricitabine" post="has been used clinically in combination with tenofovir in"/>
 <result pre="of CHB, emtricitabine has been used clinically in combination with" exact="tenofovir" post="in HIV/HBV-coinfected patients. Emtricitabine is very similar to lamivudine,"/>
 <result pre="because of high rates of resistance development.170 The rate of" exact="emtricitabine" post="resistance among patients with HBV monoinfection is 18% at"/>
 <result pre="of patients with CHB, including those resistant to lamivudine.172 Oral" exact="entecavir" post="is extensively absorbed: peak plasma concentrations occur in 30"/>
 <result pre="and oral bioavailability is almost 100%. Despite low plasma concentrations," exact="entecavir" post="maintains its potency by the long intracellular half-life of"/>
 <result pre="potency by the long intracellular half-life of its active metabolite" exact="entecavir" post="triphosphate. Entecavir is mainly excreted by glomerular filtration and"/>
 <result pre="filtration and active tubular secretion. The mechanism of action of" exact="entecavir" post="is somewhat unique because it inhibits 3 specific functions"/>
 <result pre="liver disease.173 In randomized trials of HBeAg-positive and HBeAg-negative patients," exact="entecavir" post="demonstrated better outcomes than lamivudine, with improvement in histologic"/>
 <result pre="and normalization or improvement of ALT levels. Adverse effects of" exact="entecavir" post="are generally mild and include headache, fatigue, nausea, diarrhea,"/>
 <result pre="rtT184S/A/I/L, rtS202G/C, or rtM250L. Among nucleoside-naive patients, the rate of" exact="entecavir" post="resistance is less than 1% after 5 years, but"/>
 <result pre="but patients with preexisting rtM204V/I have a higher rate of" exact="entecavir" post="resistance (51%) after 5 years.173 Lamivudine. Lamivudine is a"/>
 <result pre="years.173 Lamivudine. Lamivudine is a nucleoside analogue of cytosine. Oral" exact="lamivudine" post="provides bioavailability of about 85%, and peak serum concentrations"/>
 <result pre="kidneys.174 Lamivudine is phosphorylated intracellularly into its active 5′-triphosphate metabolite," exact="lamivudine" post="triphosphate. When the active metabolite is incorporated into viral"/>
 <result pre="In a double-blind study involving about 350 patients with CHB," exact="lamivudine" post="was associated with substantial histologic improvement, HBeAg antibody seroconversion,"/>
 <result pre="are common once treatment is discontinued.178 The adverse effects of" exact="lamivudine" post="are mild and include abdominal pain, nausea, and headache."/>
 <result pre="include abdominal pain, nausea, and headache. The clinical utility of" exact="lamivudine" post="is limited by the rapid development of antiviral resistance."/>
 <result pre="which occurs easily and confers cross-resistance. After 4 years of" exact="lamivudine" post="monotherapy, rtM204V/I resistance develops in up to 70% and"/>
 <result pre="is a synthetic thymidine nucleoside analogue. Unlike other anti-HBV drugs," exact="telbivudine" post="has no activity against HIV. Oral telbivudine is well"/>
 <result pre="other anti-HBV drugs, telbivudine has no activity against HIV. Oral" exact="telbivudine" post="is well absorbed and achieves peak plasma concentrations after"/>
 <result pre="inhibits HBV by competitive inhibition of viral DNA polymerase. Oral" exact="telbivudine" post="is approved for the treatment of CHB in patients"/>
 <result pre="inflammation and fibrosis.180, 181 It is considered more effective than" exact="lamivudine" post="and adefovir.182, 183 Compared with lamivudine, telbivudine was associated"/>
 <result pre="more effective than lamivudine and adefovir.182, 183 Compared with lamivudine," exact="telbivudine" post="was associated with a higher degree of reduction in"/>
 <result pre="or anti-HBe seroconversion. The most common adverse effects reported for" exact="telbivudine" post="are dizziness, fatigue, gastrointestinal symptoms, and rash. Unique adverse"/>
 <result pre="neuropathy or myopathy is diagnosed. The rate of resistance to" exact="telbivudine" post="is 25% after 96 weeks of treatment. Tenofovir. Tenofovir"/>
 <result pre="Tenofovir disoproxil fumarate, an acyclic nucleoside phosphonate diester analogue of" exact="adenosine" post="monophosphate, is considered one of the most potent anti-HBV"/>
 <result pre="taken with a high-fat meal. The terminal elimination half-life of" exact="tenofovir" post="is 12 to 18 hours, and it is excreted"/>
 <result pre="for conversion to tenofovir. Subsequent phosphorylation by cellular enzymes forms" exact="tenofovir" post="diphosphate, which competes with the natural substrate deoxyadenosine 5′-triphosphate"/>
 <result pre="for the treatment of CHB. In a randomized trial comparing" exact="tenofovir" post="and adefovir, a higher percentage of patients receiving tenofovir"/>
 <result pre="comparing tenofovir and adefovir, a higher percentage of patients receiving" exact="tenofovir" post="achieved HBV DNA level suppression. In HBeAg-positive patients, the"/>
 <result pre="adefovir and tenofovir.185, 186, 187, 188 The adverse effects of" exact="tenofovir" post="include gastrointestinal symptoms, dizziness, fatigue, and headache. Renal toxicities,"/>
 <result pre="have been associated with tenofovir.189, 190, 191, 192, 193 Primary" exact="tenofovir" post="resistance mutations have not been well defined. Although viruses"/>
 <result pre="than do wild-type viruses. One study reported rtA194T as a" exact="tenofovir" post="resistance mutation; however, this pattern was not confirmed in"/>
 <result pre="current standard treatment of CHC is peginterferon-α in combination with" exact="ribavirin" post="for 24 weeks (for HCV genotype 2 or 3)"/>
 <result pre="after completion of treatment. A combination regimen of peginterferon-α and" exact="ribavirin" post="results in SVR rates between 38% and 46%, and"/>
 <result pre="serine protease inhibitors to the backbone therapies of peginterferon-α and" exact="ribavirin" post="will emerge as the standard of care for the"/>
 <result pre="(SPRINT-2 [serine protease inhibitor therapy 2] trial), the addition of" exact="boceprevir" post="for 22 weeks or 44 weeks to standard therapy"/>
 <result pre="HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2) trial evaluated" exact="boceprevir" post="for the treatment of patients who had experienced a"/>
 <result pre="rates were significantly higher for patients who received peginterferon-ribavirin plus" exact="boceprevir" post="treatment for 32 weeks (59%) or 44 weeks (66%)"/>
 <result pre="logistic regression analysis, the baseline factors associated with SVR were" exact="boceprevir" post="use, previous relapse (compared with previous nonresponder), low viral"/>
 <result pre="with peginterferon and ribavirin. The most common adverse effects of" exact="boceprevir" post="are flulike illness, fatigue, nausea, dysgeusia, and anemia.194 The"/>
 <result pre="flulike illness, fatigue, nausea, dysgeusia, and anemia.194 The addition of" exact="boceprevir" post="nearly doubled the rate of anemia compared with the"/>
 <result pre="of anemia compared with the use of standard peginterferon and" exact="ribavirin" post="therapy, with many patients requiring the use of erythropoietin.195"/>
 <result pre="binding reversibly to nonstructural 3 serine protease. After oral administration," exact="telaprevir" post="achieves peak plasma concentrations in 4 to 5 hours."/>
 <result pre="3 international randomized double-blind placebo-controlled clinical trial, the addition of" exact="telaprevir" post="to the standard treatment of peginterferon-ribavirin was associated with"/>
 <result pre="Specifically, the group of patients who received 12 weeks of" exact="telaprevir" post="combined with peginterferon-ribavirin, followed by peginterferon-ribavirin for 12 weeks"/>
 <result pre="standard therapy among patients who received only 8 weeks of" exact="telaprevir" post="combined with peginterferon-ribavirin (69% vs 44%).201 In the second"/>
 <result pre="44%).201 In the second randomized phase 3 trial that evaluated" exact="telaprevir" post="in treatment-experienced patients with HCV genotype 1 infection, the"/>
 <result pre="treatment-experienced patients with HCV genotype 1 infection, the addition of" exact="telaprevir" post="to the standard treatment regimen of peginterferon-α and ribavirin"/>
 <result pre="of telaprevir to the standard treatment regimen of peginterferon-α and" exact="ribavirin" post="was associated with significantly higher SVR rates compared with"/>
 <result pre="peginterferon-ribavirin alone.202 Collectively, these studies indicate that the addition of" exact="telaprevir" post="to standard peginterferon-ribavirin therapy can significantly improve SVR rates"/>
 <result pre="ribavirin. As a result of these findings, the FDA approved" exact="telaprevir" post="(750 mg 3 times daily) for this treatment indication."/>
 <result pre="most infections, such as acyclovir for herpes simplex virus and" exact="ganciclovir" post="for CMV. However, other of these &quot;old&quot; antiviral drugs"/>
 <result pre="for CMV. However, other of these &quot;old&quot; antiviral drugs (eg," exact="amantadine" post="and rimantadine for influenza virus infections) have lost their"/>
 <result pre="However, other of these &quot;old&quot; antiviral drugs (eg, amantadine and" exact="rimantadine" post="for influenza virus infections) have lost their clinical utility"/>
 <result pre="zosterJ Infect Dis15119853623653881542 16PerazellaMACrystal-induced acute renal failureAm J Med106199945946510225250 17HelldénALyckeJVanderTSvenssonJOOdar-CederlofIStahleLThe" exact="aciclovir" post="metabolite CMMG is detectable in the CSF of subjects"/>
 <result pre="detectable in the CSF of subjects with neuropsychiatric symptoms during" exact="aciclovir" post="and valaciclovir treatmentJ Antimicrob Chemother57200694594916540518 18ErnstMEFraneyRJAcyclovir- and ganciclovir-induced neurotoxicityAnn"/>
 <result pre="the CSF of subjects with neuropsychiatric symptoms during aciclovir and" exact="valaciclovir" post="treatmentJ Antimicrob Chemother57200694594916540518 18ErnstMEFraneyRJAcyclovir- and ganciclovir-induced neurotoxicityAnn Pharmacother3219981111139475829 19WadeJCMeyersJDNeurologic"/>
 <result pre="follow-upJ Clin Microbiol42200424224914715760 23BaconTHLevinMJLearyJJSariskyRTSuttonDHerpes simplex virus resistance to acyclovir and" exact="penciclovir" post="after two decades of antiviral therapyClin Microbiol Rev16200311412812525428 24MalvyDTreilhaudMBoueeSA"/>
 <result pre="the treatment of poxvirus infectionsViruses220102740276221499452 29WolfDLRodriguezCAMucciMIngrossoADuncanBANickensDJPharmacokinetics and renal effects of" exact="cidofovir" post="with a reduced dose of probenecid in HIV-infected patients"/>
 <result pre="and renal effects of cidofovir with a reduced dose of" exact="probenecid" post="in HIV-infected patients with cytomegalovirus retinitisJ Clin Pharmacol432003435112520627 30CundyKCClinical"/>
 <result pre="retinitisJ Clin Pharmacol432003435112520627 30CundyKCClinical pharmacokinetics of the antiviral nucleotide analogues" exact="cidofovir" post="and adefovirClin Pharmacokinet36199912714310092959 31KendleJBFan-HavardPCidofovir in the treatment of cytomegaloviral"/>
 <result pre="of isolates from cytomegalovirus retinitis patients receiving first- or second-line" exact="cidofovir" post="therapy: relationship to clinical outcomeJ Infect Dis1781998182118259815243 33JabsDAEngerCFormanMDunnJPThe Cytomegalovirus"/>
 <result pre="Retinitis and Viral Resistance Study GroupIncidence of foscarnet resistance and" exact="cidofovir" post="resistance in patients treated for cytomegalovirus retinitisAntimicrob Agents Chemother421998224022449736542"/>
 <result pre="patients treated for cytomegalovirus retinitisAntimicrob Agents Chemother421998224022449736542 34SnoeckRDe ClercqERole of" exact="cidofovir" post="in the treatment of DNA virus infections, other than"/>
 <result pre="patientsCurr Opin Investig Drugs3200215611566 35ChaSJohnstonLNatkunamYBrownJTreatment of verruca vulgaris with topical" exact="cidofovir" post="in an immunocompromised patient: a case report and review"/>
 <result pre="case report and review of the literatureTranspl Infect Dis7200515816116390407 36LamothFPascualMErardVVenetzJPNseirGMeylanPLow-dose" exact="cidofovir" post="for the treatment of polyomavirus-associated nephropathy: two case reports"/>
 <result pre="two case reports and review of the literatureAntivir Ther1320081001100919195325 37ToroJRSanchezSTurianskyGBlauveltATopical" exact="cidofovir" post="for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial"/>
 <result pre="Dis17019945705728077713 39BryantPSasadeuszJCarapetisJWatersKCurtisNSuccessful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous" exact="cidofovir" post="in a childPediatr Infect Dis J2020011083108611734717 40KoppTGeusauARiegerAStinglGSuccessful treatment of"/>
 <result pre="treatment of an aciclovir-resistant herpes simplex type 2 infection with" exact="cidofovir" post="in an AIDS patientBr J Dermatol147200213413812100196 41GarveyLThomsonECTaylorGPProgressive multifocal leukoencephalopathy:"/>
 <result pre="inhibitors and cidofovir: a case seriesAIDS20200679179316514320 42MarraCMRajicicNBarkerDEA pilot study of" exact="cidofovir" post="for progressive multifocal leukoencephalopathy in AIDSAIDS1620021791179712218391 43RazonableRRAksamitAJWrightAJWilsonJWCidofovir treatment of"/>
 <result pre="patient receiving highly active antiretroviral therapyMayo Clin Proc7620011171117511702907 44Segarra-NewnhamMVodoloKMUse of" exact="cidofovir" post="in progressive multifocal leukoencephalopathyAnn Pharmacother35200174174411408993 45ViallardJFLazaroEEllieEImprovement of progressive multifocal"/>
 <result pre="progressive multifocal leukoencephalopathyAnn Pharmacother35200174174411408993 45ViallardJFLazaroEEllieEImprovement of progressive multifocal leukoencephalopathy after" exact="cidofovir" post="therapy in a patient with a destructive polyarthritisInfection352007333617297588 46CesaroSHirschHHFaraciMCidofovir"/>
 <result pre="associated with cidofovirJ Antimicrob Chemother60200719319417496056 49AmbatiJWynneKBAngerameMCRobinsonMRAnterior uveitis associated with intravenous" exact="cidofovir" post="use in patients with cytomegalovirus retinitisBr J Ophthalmol8319991153115810502577 50TsengALMortimerCBSalitIEIritis"/>
 <result pre="Pharmacother33199916717110084411 51GillKSWoodMJThe clinical pharmacokinetics of famciclovirClin Pharmacokinet311996188827396 52FaroSA review of" exact="famciclovir" post="in the management of genital herpesInfect Dis Obstet Gynecol6199838439678146"/>
 <result pre="update and review of new single-day dosing indicationsCutis802007778117725069 54SaltzmanRJurewiczRBoonRSafety of" exact="famciclovir" post="in patients with herpes zoster and genital herpesAntimicrob Agents"/>
 <result pre="Group; Cytomegalovirus Cooperative Study GroupA randomized, controlled study of intravenous" exact="ganciclovir" post="therapy for cytomegalovirus peripheral retinitis in patients with AIDSJ"/>
 <result pre="with AIDSJ Infect Dis16819935575638394858 69DrewWLIvesDLalezariJPSyntex Cooperative Oral Ganciclovir Study GroupOral" exact="ganciclovir" post="as maintenance treatment for cytomegalovirus retinitis in patients with"/>
 <result pre="Transplantation Study GroupRandomised trial of efficacy and safety of oral" exact="ganciclovir" post="in the prevention of cytomegalovirus disease in liver-transplant recipients"/>
 <result pre="Lancet. 1998;351(9100):454]Lancet3501997172917339413463 71EidAJArthursSKDezielPJWilhelmMPRazonableRREmergence of drug-resistant cytomegalovirus in the era of" exact="valganciclovir" post="prophylaxis: therapeutic implications and outcomesClin Transplant22200816217018339135 72SariskyRTBaconTHBoonRJProfiling penciclovir susceptibility"/>
 <result pre="era of valganciclovir prophylaxis: therapeutic implications and outcomesClin Transplant22200816217018339135 72SariskyRTBaconTHBoonRJProfiling" exact="penciclovir" post="susceptibility and prevalence of resistance of herpes simplex virus"/>
 <result pre="simplex virus isolates across eleven clinical trialsArch Virol14820031757176914505088 73BaconTHBoydMRActivity of" exact="penciclovir" post="against Epstein-Barr virusAntimicrob Agents Chemother391995159916027492112 74SpruanceSLReaTLThomingCTuckerRSaltzmanRBoonRTopical Penciclovir Collaborative Study"/>
 <result pre="76SpruanceSLTyringSKDeGregorioBMillerCBeutnerKValaciclovir HSV Study GroupA large-scale, placebo-controlled, dose-ranging trial of peroral" exact="valaciclovir" post="for episodic treatment of recurrent herpes genitalisArch Intern Med1561996172917358694673"/>
 <result pre="disease in immunocompromised hostsExpert Rev Anti Infect Ther22004274115482169 80BrownFBankenLSaywellKArumIPharmacokinetics of" exact="valganciclovir" post="and ganciclovir following multiple oral dosages of valganciclovir in"/>
 <result pre="immunocompromised hostsExpert Rev Anti Infect Ther22004274115482169 80BrownFBankenLSaywellKArumIPharmacokinetics of valganciclovir and" exact="ganciclovir" post="following multiple oral dosages of valganciclovir in HIV- and"/>
 <result pre="80BrownFBankenLSaywellKArumIPharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of" exact="valganciclovir" post="in HIV- and CMV-seropositive volunteersClin Pharmacokinet37199916717610496303 81WiltshireHHirankarnSFarrellCPharmacokinetic profile of"/>
 <result pre="valganciclovir in HIV- and CMV-seropositive volunteersClin Pharmacokinet37199916717610496303 81WiltshireHHirankarnSFarrellCPharmacokinetic profile of" exact="ganciclovir" post="after its oral administration and from its prodrug, valganciclovir,"/>
 <result pre="valganciclovir, in solid organ transplant recipientsClin Pharmacokinet44200549550715871635 82CaldesAColomHArmendarizYPopulation pharmacokinetics of" exact="ganciclovir" post="after intravenous ganciclovir and oral valganciclovir administration in solid"/>
 <result pre="organ transplant recipientsClin Pharmacokinet44200549550715871635 82CaldesAColomHArmendarizYPopulation pharmacokinetics of ganciclovir after intravenous" exact="ganciclovir" post="and oral valganciclovir administration in solid organ transplant patients"/>
 <result pre="Pharmacokinet44200549550715871635 82CaldesAColomHArmendarizYPopulation pharmacokinetics of ganciclovir after intravenous ganciclovir and oral" exact="valganciclovir" post="administration in solid organ transplant patients infected with cytomegalovirusAntimicrob"/>
 <result pre="patients infected with cytomegalovirusAntimicrob Agents Chemother5320094816482419738014 83MartinDFSierra-MaderoJWalmsleySA controlled trial of" exact="valganciclovir" post="as induction therapy for cytomegalovirus retinitisN Engl J Med34620021119112611948271"/>
 <result pre="for cytomegalovirus retinitisN Engl J Med34620021119112611948271 84PayaCHumarADominguezEEfficacy and safety of" exact="valganciclovir" post="vs. oral ganciclovir for prevention of cytomegalovirus disease in"/>
 <result pre="Engl J Med34620021119112611948271 84PayaCHumarADominguezEEfficacy and safety of valganciclovir vs. oral" exact="ganciclovir" post="for prevention of cytomegalovirus disease in solid organ transplant"/>
 <result pre="solid organ transplant recipientsAm J Transplant4200461162015023154 85KhouryJAStorchGABohlDLProphylactic versus preemptive oral" exact="valganciclovir" post="for the management of cytomegalovirus infection in adult renal"/>
 <result pre="infection in adult renal transplant recipientsAm J Transplant620062134214316780548 86SnydmanDRUse of" exact="valganciclovir" post="for prevention and treatment of cytomegalovirus disease [editorial]Clin Infect"/>
 <result pre="prevention and treatment of cytomegalovirus disease [editorial]Clin Infect Dis462008282918171209 87EinseleHReusserPBornhauserMOral" exact="valganciclovir" post="leads to higher exposure to ganciclovir than intravenous ganciclovir"/>
 <result pre="[editorial]Clin Infect Dis462008282918171209 87EinseleHReusserPBornhauserMOral valganciclovir leads to higher exposure to" exact="ganciclovir" post="than intravenous ganciclovir in patients following allogeneic stem cell"/>
 <result pre="87EinseleHReusserPBornhauserMOral valganciclovir leads to higher exposure to ganciclovir than intravenous" exact="ganciclovir" post="in patients following allogeneic stem cell transplantationBlood10720063002300816352807 88LenOGavaldaJAguadoJMValganciclovir as"/>
 <result pre="cytomegalovirus disease in solid organ transplant recipientsClin Infect Dis462008202718171208 89AsbergAHumarARollagHOral" exact="valganciclovir" post="is noninferior to intravenous ganciclovir for the treatment of"/>
 <result pre="transplant recipientsClin Infect Dis462008202718171208 89AsbergAHumarARollagHOral valganciclovir is noninferior to intravenous" exact="ganciclovir" post="for the treatment of cytomegalovirus disease in solid organ"/>
 <result pre="91De ClercqEAntiviral drugs in current clinical useJ Clin Virol30200411513315125867 92TappendenPJacksonRCooperKAmantadine," exact="oseltamivir" post="and zanamivir for the prophylaxis of influenza (including a"/>
 <result pre="drugs in current clinical useJ Clin Virol30200411513315125867 92TappendenPJacksonRCooperKAmantadine, oseltamivir and" exact="zanamivir" post="for the prophylaxis of influenza (including a review of"/>
 <result pre="systematic review and economic evaluationHealth Technol Assess131120091246iii, ix-xii 93BettsRFAmantadine and" exact="rimantadine" post="for the prevention of influenza ASemin Respir Infect419893043102697053 94KrumbholzASchmidtkeMBergmannSHigh"/>
 <result pre="the prevention of influenza ASemin Respir Infect419893043102697053 94KrumbholzASchmidtkeMBergmannSHigh prevalence of" exact="amantadine" post="resistance among circulating European porcine influenza A virusesJ Gen"/>
 <result pre="Virol442009919319019729 96HaydenFGHayAJEmergence and transmission of influenza A viruses resistant to" exact="amantadine" post="and rimantadineCurr Top Microbiol Immunol17619921191301600749 97HaydenFGSperberSJBelsheRBCloverRDHayAJPykeSRecovery of drug-resistant influenza"/>
 <result pre="pandemicJ Antimicrob Chemother55suppl 12005i5i2115709056 99SugayaNTamuraDYamazakiMComparison of the clinical effectiveness of" exact="oseltamivir" post="and zanamivir against influenza virus infection in childrenClin Infect"/>
 <result pre="Chemother55suppl 12005i5i2115709056 99SugayaNTamuraDYamazakiMComparison of the clinical effectiveness of oseltamivir and" exact="zanamivir" post="against influenza virus infection in childrenClin Infect Dis47200833934518582202 100KhazeniNBravataDMHoltyJEUyekiTMStaveCDGouldMKSystematic"/>
 <result pre="neuraminidase inhibitorsJAMA29720071435144217405969 106FreundBGravensteinSElliottMMillerIZanamivir: a review of clinical safetyDrug Saf21199926728110514019 107GaurAHBaggaBBarmanSIntravenous" exact="zanamivir" post="for oseltamivir-resistant 2009 H1N1 influenza [letter]N Engl J Med36212010888920032317"/>
 <result pre="HBeAg-positive chronic hepatitis BN Engl J Med35220052682269515987917 117MarcellinPLauGKBoninoFPeginterferon alfa-2a alone," exact="lamivudine" post="alone, and the two in combination in patients with"/>
 <result pre="Med35120041206121715371578 118JanssenHLvan ZonneveldMSenturkHPegylated Interferon alfa-2b alone or in combination with" exact="lamivudine" post="for HBeAg-positive chronic hepatitis B: a randomised trialLancet365200512312915639293 119FarciPMandasACoianaATreatment"/>
 <result pre="for chronic hepatitis CCochrane Database Syst Rev12010CD00544520091577 128FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infectionN Engl J Med347200297598212324553"/>
 <result pre="hepatitis C virus infectionN Engl J Med347200297598212324553 129MannsMPMcHutchisonJGGordonSCPeginterferon alfa-2b plus" exact="ribavirin" post="compared with interferon alfa-2b plus ribavirin for initial treatment"/>
 <result pre="Med347200297598212324553 129MannsMPMcHutchisonJGGordonSCPeginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus" exact="ribavirin" post="for initial treatment of chronic hepatitis C: a randomised"/>
 <result pre="in HIV-infected patients: a randomized controlled trialJAMA29220042839284815598915 132TorrianiFJRodriguez-TorresMRockstrohJKPeginterferon Alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infection in HIV-infected patientsN"/>
 <result pre="infection in HIV-infected patientsN Engl J Med351200443845015282351 133ChungRTAndersenJVolberdingPPeginterferon Alfa-2a plus" exact="ribavirin" post="versus interferon alfa-2a plus ribavirin for chronic hepatitis C"/>
 <result pre="J Med351200443845015282351 133ChungRTAndersenJVolberdingPPeginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C in HIV-coinfected personsN Engl J"/>
 <result pre="J Med310198432356689738 147AgestaNZabalaRDiaz-PerezJLAlopecia areata during interferon alpha-2b/ribavirin therapyDermatology205200230030112399683 148WadeJRSnoeckEDuffFLambMJorgaKPharmacokinetics of" exact="ribavirin" post="in patients with hepatitis C virusBr J Clin Pharmacol62200671071417118126"/>
 <result pre="clearance of intravenously administered ribavirinAntimicrob Agents Chemother3419904894902334164 150GishRGTreating HCV with" exact="ribavirin" post="analogues and ribavirin-like moleculesJ Antimicrob Chemother57200681316293677 151GluudLLMarchesiniEIorioAPeginterferon plus ribavirin"/>
 <result pre="with ribavirin analogues and ribavirin-like moleculesJ Antimicrob Chemother57200681316293677 151GluudLLMarchesiniEIorioAPeginterferon plus" exact="ribavirin" post="for chronic hepatitis C in patients with human immunodeficiency"/>
 <result pre="infants and young childrenCochrane Database Syst Rev2007CD00018117253446 153PelaezALyonGMForceSDEfficacy of oral" exact="ribavirin" post="in lung transplant patients with respiratory syncytial virus lower"/>
 <result pre="Lung Transplant282009677119134533 154KnowlesSRPhillipsEJDresserLMatukasLCommon adverse events associated with the use of" exact="ribavirin" post="for severe acute respiratory syndrome in CanadaClin Infect Dis3720031139114214523782"/>
 <result pre="156McJunkinJEKhanRde los ReyesECTreatment of severe La Crosse encephalitis with intravenous" exact="ribavirin" post="following diagnosis by brain biopsyPediatrics9919972612679024460 157ChongHTKamarulzamanATanCTTreatment of acute Nipah"/>
 <result pre="J Med314198620263940312 159HugginsJWHsiangCMCosgriffTMProspective, double-blind, concurrent, placebo-controlled clinical trial of intravenous" exact="ribavirin" post="therapy of hemorrhagic fever with renal syndromeJ Infect Dis1641991111911271683355"/>
 <result pre="Congo-haemorrhagic fever treated with oral ribavirinLancet34619954724757637481 161MardaniMJahromiMKNaieniKHZeinaliMThe efficacy of oral" exact="ribavirin" post="in the treatment of Crimean-Congo hemorrhagic fever in IranClin"/>
 <result pre="with adefovir dipivoxilJ Antimicrob Chemother59200782783217332007 170LimSGNgTMKungNA double-blind placebo-controlled study of" exact="emtricitabine" post="in chronic hepatitis BArch Intern Med1662006495616401810 171SimsKAWoodlandAMEntecavir: a new"/>
 <result pre="BDrugs6920091003103319496629 174JohnsonMAMooreKHYuenGJByeAPakesGEClinical pharmacokinetics of lamivudineClin Pharmacokinet3619994166 175DienstagJLPerrilloRPSchiffERBartholomewMVicaryCRubinMA preliminary trial of" exact="lamivudine" post="for chronic hepatitis B infectionN Engl J Med3331995165716617477217 176DienstagJLSchiffERWrightTLLamivudine"/>
 <result pre="J Med34119991256126310528035 177LaiCLChienRNLeungNWAsia Hepatitis Lamivudine Study GroupA one-year trial of" exact="lamivudine" post="for chronic hepatitis BN Engl J Med339199861689654535 178HonkoopPde ManRAHeijtinkRASchalmSWHepatitis"/>
 <result pre="Med339199861689654535 178HonkoopPde ManRAHeijtinkRASchalmSWHepatitis B reactivation after lamivudineLancet3461995115611577475613 179ZhouXJKeJSallasWMFarrellCMayersDLPentikisHSPopulation pharmacokinetics of" exact="telbivudine" post="and determination of dose adjustment for patients with renal"/>
 <result pre="agents: a focus on telbivudineInt J Clin Pract6020061295129916981973 182LaiCLGaneELiawYFTelbivudine versus" exact="lamivudine" post="in patients with chronic hepatitis BN Engl J Med35720072576258818094378"/>
 <result pre="183ChanHLHeathcoteEJMarcellinPTreatment of hepatitis B e antigen positive chronic hepatitis with" exact="telbivudine" post="or adefovir: a randomized trialAnn Intern Med147200774575417909201 184KearneyBPFlahertyJFShahJTenofovir disoproxil"/>
 <result pre="187WongSNLokASTenofovir disoproxil fumarate: role in hepatitis B treatmentHepatology44200630931316871562 188ReijndersJGJanssenHLPotency of" exact="tenofovir" post="in chronic hepatitis B: mono or combination therapy?J Hepatol48200838338618191272"/>
 <result pre="Patient Care STDS2220089910318260800 191SchmidSOpravilMModdelMAcute interstitial nephritis of HIV-positive patients under" exact="atazanavir" post="and tenofovir therapy in a retrospective analysis of kidney"/>
 <result pre="STDS2220089910318260800 191SchmidSOpravilMModdelMAcute interstitial nephritis of HIV-positive patients under atazanavir and" exact="tenofovir" post="therapy in a retrospective analysis of kidney biopsiesVirchows Arch450200766567017464512"/>
 <result pre="treated with the protease inhibitor telaprevirGastroenterology13220071767177717484874 199McHutchisonJGEversonGTGordonSCTelaprevir with peginterferon and" exact="ribavirin" post="for chronic HCV genotype 1 infectionN Engl J Med36020091827183819403902"/>
 <result pre="infectionN Engl J Med36020091827183819403902 200HézodeCForestierNDusheikoGTelaprevir and peginterferon with or without" exact="ribavirin" post="for chronic HCV infectionN Engl J Med36020091839185019403903 201JacobsonIMMcHutchisonJGDusheikoGTelaprevir for"/>
</results>
